Market Intelligence Report: Feasibility Study for an Advanced Oncology Center of Excellence in Abu Dhabi

Executive Viability Abstract

This feasibility study evaluates the establishment of a 50-bed Advanced Oncology Center of Excellence in Abu Dhabi. The project addresses a critical gap in high-end radiotherapy and immunotherapy services, targeting a 22% IRR over a 10-year horizon. Leveraging a favorable regulatory environment under the Department of Health (DOH) and the Federal Authority for Nuclear Regulation (FANR), the facility is positioned to capture domestic demand and medical tourism from the wider GCC region.

## 1. Executive Feasibility Thesis The Abu Dhabi oncology market is currently characterized by a supply-demand mismatch in sub-specialized cancer care, particularly in pediatric oncology and advanced radiotherapy. With the UAE's National Strategy for Wellbeing 2031 prioritizing non-communicable diseases, this project aims to repatriate the estimated $250M annual outbound spend for cancer treatment. **Core Assumptions:** - **Target Market Size:** 1.6 million residents in Abu Dhabi Emirate, with a 4.2% annual increase in diagnosed cancer cases. - **Cost of Capital (WACC):** 8.5%, reflecting a low-risk sovereign environment but specialized healthcare premiums. - **Capacity Utilization:** 35% in Year 1, scaling to 80% by Year 4. - **Primary Revenue Stream:** 65% from Tier-1 Private Insurance (Daman/Thiqa) and 35% from international medical tourists. ## 2. Technical Feasibility & Operational Specifications The facility will be a 12,000 sqm purpose-built structure. Technical specifications include: - **Linear Accelerators (Linac):** Two Varian TrueBeam or equivalent units with 6DOF couches. - **Radiopharmacy:** Grade A cleanroom for on-site isotope preparation, reducing dependency on external suppliers. - **Diagnostic Imaging:** 3.0T MRI and a 128-slice PET-CT for precise staging. - **Inpatient Care:** 50 private suites designed for long-term stays, incorporating HEPA-filtration and positive pressure for immunocompromised patients. - **IT Infrastructure:** AI-driven oncology management systems (e.g., ARIA/Eclipse) integrated with the Malaffi HIE (Health Information Exchange) platform. ## 3. Detailed Capital Expenditure (Capex) | Item | Unit Cost (USD) | Total Cost (USD) | Reasoning | | :--- | :--- | :--- | :--- | | **Linac Bunkers (Construction)** | $1,200,000 | $2,400,000 | Specialized high-density concrete shielding (2m+ thickness) and lead lining. | | **Medical Equipment (Linac)** | $4,500,000 | $9,000,000 | Dual-energy photon beams with SBRT/SRS capabilities. | | **PET-CT Scanner** | $2,500,000 | $2,500,000 | Crucial for metabolic imaging and treatment monitoring. | | **Cyclotron/Hot Lab** | $3,500,000 | $3,500,000 | On-site production of FDG to avoid delivery decay and logistics delays. | | **Fit-out/Finishing** | $3,500/sqm | $42,000,000 | Clinical-grade finishes compliant with DOH Facility Guidelines. | | **Pre-operating Costs** | $1,500,000 | $1,500,000 | Licensing, recruitment, and JCI accreditation preparation. | | **Total Capex** | -- | **$60,900,000** | Including 10% contingency reserve. | ## 4. Realistic Operating Expenditure (Opex) Operating costs are dominated by specialized labor and pharmaceutical procurement. - **Staffing (Monthly):** - Senior Oncologists (6): $40,000 per month each (total $240,000). - Medical Physicists (2): $18,000 per month each (total $36,000). - Oncology Certified Nurses (25): $6,500 per month each (total $162,500). - **Consumables:** Estimated at 38% of revenue, driven by high-cost immunotherapy drugs (Keytruda/Opdivo) and chemotherapy reagents. - **Equipment Maintenance (AMC):** $1,200,000 annually. Service contracts for Linacs and PET-CT typically cost 8-10% of capital value per annum after Year 1. - **Utilities & Facility Mgmt:** $120,000 monthly, factoring in the extreme cooling requirements for imaging magnets and shielding ventilation. ## 5. Financial Model & Sensitivity Range (ROI/IRR) The base case assumes a 10-year projection with a terminal value based on a 7x EBITDA multiple. **Sensitivity Analysis:** | Case | Variable Change | 10-Year IRR | Payback Period | | :--- | :--- | :--- | :--- | | **Base Case** | Projected volumes/pricing | 21.4% | 5.8 Years | | **Optimistic** | +15% Medical Tourism Yield | 26.8% | 4.5 Years | | **Pessimistic** | -10% DOH Reimbursement Rates | 14.2% | 8.2 Years | **Financial Assumptions:** - Tax: 9% UAE Corporate Tax (applicable from June 2023). - Depreciation: 10 years for equipment; 25 years for building structures. ## 6. Regulatory & Environmental Compliance Frameworks Abu Dhabi presents a dual-layered regulatory requirement: - **DOH (Department of Health):** Mandatory PQR (Professional Qualification Requirements) for all medical staff. The facility must adhere to the 'Health Facility Guidelines' (HFG) for space planning. - **FANR (Federal Authority for Nuclear Regulation):** Strict licensing required for the import, storage, and usage of radioactive sources. Requires a Resident Radiation Safety Officer (RSO). - **Environmental:** Compliance with TADWEER (Abu Dhabi Waste Management Center) for hazardous biological and chemical waste disposal is mandatory, requiring specialized contract hauling. ## 7. Strategic Takeaways 1. **Clinical Differentiation:** To succeed, the center must secure an 'Academic Health System' status or a partnership with a Western Tier-1 brand (e.g., Mayo Clinic, Cleveland Clinic) to build immediate trust. 2. **Financial Hedge:** High opex related to drugs should be mitigated through bulk procurement agreements with local distributors like Rafed. 3. **Localization:** Emphasis on Emirati clinical training programs will be a key driver for long-term sustainability and government relations. 4. **Feasibility Verdict:** The project is financially viable and strategically aligned with Abu Dhabi's 2030 vision, provided that high-end radiotherapy volumes are secured via insurance network inclusion (Daman's Thiqa network).